Semaglutide Use Surges Among Gen X, Impacting Aesthetics Market
Key Insights
Semaglutide usage has surged due to FDA approval for weight loss management, providing a regulated avenue for prescription.
Gen X (born 1965-1980) comprises the largest group of semaglutide patients (44%) due to higher disposable income and health concerns.
Semaglutide adoption is driving new patients to aesthetics practices, with potential shifts in spending across different aesthetic treatments.
The use of semaglutide has seen a significant increase in recent years, largely driven by FDA approval for its expanded use in weight management. This regulatory endorsement has provided a legal and controlled pathway for the drug to be prescribed, contributing to its widespread adoption.
Demographic Trends in Semaglutide Usage
Data indicates that Gen X (born between 1965 and 1980) represents the largest demographic of semaglutide users, accounting for approximately 44% of all patients in 2024. This trend is attributed to several factors, including higher disposable incomes during their peak earning years, enabling them to afford the relatively high cost of semaglutide. Additionally, individuals in this age group often experience more pronounced health concerns related to weight management, such as obesity (search) and diabetes (search), which motivates them to seek effective weight loss solutions.
The breakdown of semaglutide patients in the U.S. by age group as of 2024 is as follows:
- Boomer & Older (born on or before 1964): 18%
- Gen X (born 1965 to 1980): 44%
- Millennial (born 1981 to 1996): 32%
- Gen Z & Younger (Born on or after 1997): 6%
Impact on the Aesthetics Market
The widespread adoption of semaglutide is expected to have a substantial impact on the aesthetics industry. The rapid changes in patient body composition are driving several notable trends:
- New Patient Growth: Approximately 50% of patients purchasing semaglutide at aesthetics practices are new customers.
- New Patient Retention: These new patients are returning for various services, including lipo shots, vitamin and supplement purchases, and neurotoxin injections.
- Increased Spending: Existing aesthetics patients undergoing semaglutide treatment are seeing an average increase in annual aesthetics spending of 30% to 40%, largely due to the cost of semaglutide itself.
- Shifting Spending Patterns: Analysis of 6,500 patients revealed that while overall aesthetics spending may increase, spending on other categories like neurotoxins, energy-based devices, and dermal fillers may decrease as the cost of semaglutide takes precedence.
Emerging Opportunities for Aesthetic Practices
The surge in semaglutide usage presents significant opportunities for aesthetic practices. Practices should focus on promoting a range of services to new patients to maximize upselling potential and convert them into loyal customers. Physicians should also be attentive to patients' physical changes during treatment, as these changes may create new aesthetic needs. For example, patients commonly experience sagging facial skin, often referred to as "Ozempic Face," which may require dermal fillers to restore lost volume.